Eli Lilly and Incyte receive EC ’s marketing authorisation approval for Olumiant

Eli Lilly and Incyte have secured marketing authorisation approval for Olumiant (baricitinib) 4mg and 2mg film-coated tablets from the European Commission (EC) to treat moderate-to-severe active rheumatoid arthritis (RA) in adult patients.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news